SCHEMBL1316686

SCHEMBL1316686

CC(C)(C)OC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1cc(N2CCC3(CC2)OCCO3)ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.43
HDAC1 Q13547 7/20 0.40
USP2 O75604 3/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP3A4 P08684 1/20 0.38
PTPN11 Q06124 1/20 0.37
KDM4E B2RXH2 1/20 0.36
APOBEC3A P31941 1/20 0.36
GFER P55789 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
CYP1A2 P05177 2/20 0.36
MAPK1 P28482 2/20 0.36
WDR5 P61964 2/20 0.36
CYP2D6 P10635 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC3 O15379 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12117860 0.92 BACE1 (0.43) BACE1HDAC1USP2HSD17B10CYP3A4
SCHEMBL1316547 0.89 HDAC1 (0.45) BACE1HDAC1USP2CYP3A4CYP1A2
SCHEMBL13206531 0.88 ACLY (0.43) BACE1HDAC1USP2HSD17B10CYP3A4
SCHEMBL1316253 0.87 HDAC1 (0.44) BACE1HDAC1KDM4EAPOBEC3AGFER
SCHEMBL1316248 0.87 LRRK2 (0.47) BACE1CYP3A4
SCHEMBL1315634 0.86 WDR5 (0.49) BACE1HDAC1MAPK1WDR5HDAC2
SCHEMBL1327669 0.85 HDAC1 (0.42) BACE1HDAC1KDM4EAPOBEC3AGFER
SCHEMBL1316807 0.85 HDAC1 (0.42) BACE1HDAC1WDR5HDAC2HDAC3
SCHEMBL1327665 0.85 HDAC1 (0.42) BACE1HDAC1CYP3A4KDM4EAPOBEC3A
SCHEMBL12117816 0.84 BACE1 (0.44) BACE1HDAC1USP2KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 BACE1 3622/4885HDAC1 73/4885USP2 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.